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Abstract
Immunotherapy is widely regarded to have the ability to transform the treatment of cancer,
with immune checkpoint inhibitors already in use for cancers such as advanced melanoma and
non-small cell lung cancer (NSCLC). However, despite its potential, the widespread adoption of
immunotherapy for the treatment of other cancers has been largely limited. This can be partly
attributed to additional immunosuppressive mechanisms in the tumor microenvironment that
help promote and maintain a state of T cell exhaustion. As such, the exploration of
combinatory immunotherapies is an active area of research and includes the combination of
immune checkpoint inhibitors with cytotoxic therapies, cancer vaccines and monoclonal
antibodies against other co-inhibitory and co-stimulatory receptors. Strategies are also being
employed to improve the homing, extravasation and survival of chimeric antigen receptor
(CAR)-T cells in the tumor microenvironment. Furthermore, the development of
immunotherapies targeted to one or multiple neoantigens unique to a specific tumor may act to
enhance anti-tumor immunity, as well as reduce immune-related adverse events (irAEs). As
immunotherapy evolves to become a mainstay treatment for cancer, it is imperative that
optimum treatment regimens that maximize efficacy and limit toxicity are developed.
Foremost, appropriate biomarkers must be identified to help tailor combinatory
immunotherapies to the individual patient and hence pave the way to a new era of personalized
medicine. 
Categories: Oncology
Keywords: immunotherapy, combination immunotherapy, immune check point inhibitors, car t-cell
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Introduction And Background
The notion of harnessing the host’s immune system to eliminate cancer has been well-
established for years, even though the field has only started taking off relatively recently. It
stems from the knowledge that the immune system is a critical player in the prevention, as well
as the development and progression of cancer. The prevention of tumorigenesis is achieved via
numerous mechanisms, including protection against viral-induced tumors and suppression of
tumor-promoting inflammatory environments. Arguably, the most important mechanism is
that malignantly transformed cells often co-express ligands associated with DNA damage and
tumor antigens, which can be recognized and targeted by the innate immune system and
lymphocytes of the adaptive immune system, respectively, in a process termed immune
surveillance [1]. 
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The ability of the immune system to recognize antigens on malignant cells and target them for
destruction forms the foundations of immunotherapy [2]. However, a distinguishing hallmark
of cancer is its ability to evade immune destruction in a number of distinct ways. Notably,
immune editing provides a selective pressure that gives rise to a less immunogenic population
of neoplastic cells [2-3]. This is augmented by other immune-evading processes, including
disruption of T cell function and signaling, defective antigen presentation, and the altered
production of immune-suppressive mediators such as inhibitory cytokines and
immunosuppressive cells. These processes ultimately lead to the proliferation of malignant
cells, clinically manifesting as cancer [3]. 
Immunotherapy holds a lot of promise, not least because it avoids the many limitations of
chemotherapy and radiotherapy - the current mainstay treatments for cancer. These limitations
include systemic toxicities, lack of specificity for malignant cells, recurrence of drug-resistant
tumors, and the inability to target and treat micrometastasis or subclinical disease [4]. The
main forms of immunotherapy are immune checkpoint inhibitors, adoptive cell transfer,
cytokine therapy, and cancer vaccines. As cancer immunotherapy effectively targets the
immune system, in principle it should be able to treat a broad range of tumor types
independent of the underlying histology or driver mutations. However, to date, immunotherapy
has only demonstrated efficacy in a select group of cancers and usually in a minority of patients
with those cancers, limiting its use as a treatment. Consequently, strategies for expanding its
use is an active area of research and will be the focus of this review. 
Review
Immune checkpoint inhibitors
Immune checkpoint inhibitors have achieved notable clinical success as a novel class of
immunotherapy, particularly in patients with advanced melanoma and non-small cell lung
cancer (NSCLC) [4]. The primary effector cells of the adaptive immune response to cancer are T
lymphocytes, including T helper cells and cytotoxic T lymphocytes (CTLs). These cells are
primed and activated through interaction of their T cell receptors (TCRs) with tumor antigens
presented on major histocompatibility complexes (MHCs) by antigen-presenting cells (APCs).
Immune checkpoints essentially provide the co-stimulatory or co-inhibitory signals that
regulate this process. Specifically, cytotoxic lymphocyte-associated protein 4 (CTLA-4) is a co-
inhibitory receptor which, through binding to CD80 (B7.1) and CD86 (B7.2) ligands expressed
on tumor cells and APCs, inhibits the process of T cell priming and activation. Normally, after
priming and activation, CTLs migrate to the tumor where they exert their cytotoxic activity.
This process is also controlled by immune checkpoints including programmed cell death
protein 1 (PD-1) receptor, a co-inhibitory receptor present on activated T cells, regulatory T
(Treg) cells, B cells, and natural killer (NK) cells. The ligands of this receptor, PD-L1 and PD-L2,
are also expressed by both tumor cells and APCs, and once bound lead to T cell apoptosis and
exhaustion, providing protection against CTL-mediated killing. As such, these inhibitory
pathways are often found to be upregulated in cancer, as one of many mechanisms to evade
immune surveillance. 
Given the crucial role of immune checkpoints in suppressing the anti-tumor immune response,
the use of monoclonal antibodies (mAbs) as immune checkpoint inhibitors targeting CTLA-4
and PD-1/PD-L1 appears very promising, with their mechanism of action shown in Figure
1. Examples of approved immune checkpoint inhibitors include ipilimumab, an anti-CTLA-4
mAb, and nivolumab, an anti-PD-1 mAb. However, despite immune checkpoint inhibitors
showing anti-tumor activity in a number of different malignancies, less than 25% of patients
achieve any benefit [5]. This may in part be due to additional suppressive mechanisms that help
contribute and maintain T cell exhaustion, preventing the immune system from mounting a
sufficient response. For instance, targeting the PD-1 pathway alone does not result in complete
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restoration of T cell function and in fact expression of alternative co-inhibitory immune
checkpoints has been associated with resistance to PD-1 blockade [6]. One such inhibitory
receptor that is expressed on CTLs and Treg cells during exhaustion is lymphocyte activation
gene 3 protein (LAG3), with efficacy studies demonstrating an enhanced response in melanoma
patients treated with both nivolumab and relatlimab, an anti-LAG3 mAb [7]. Similarly, T cell
immunoglobulin and mucin domain-containing 3 (TIM3) are also thought to maintain a state of
T cell exhaustion and are found to be expressed on lymphocytes in a range of tumors. In fact,
preclinical studies have already demonstrated a superior synergistic effect of combined TIM3
and PD-1 blockade in cancers, such as melanoma, gastric cancer, hepatocellular carcinoma
(HCC), and acute myeloid leukemia (AML), which is superior to targeting either pathway
alone [6,8]. 
FIGURE 1: Mechanism of action of anti-CTLA-4 and anti-PD-L1
immune checkpoint inhibitors
CTLA-4, cytotoxic lymphocyte-associated protein 4; MHC, major histocompatibility complex; PD-
1, programmed cell death protein 1; TCR, T cell receptor; Treg cell, regulatory T cell
The most studied immunotherapy combination is combined PD-1 and CTLA-4 blockade. This
combination has been shown to be able to overcome T cell exhaustion and restore anti-tumor
immunity in a wide range of cancers, with phase III trials demonstrating superiority of this
approach in the treatment of melanoma, renal cell carcinoma, and NSCLC [9-11]. Other cancers
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being explored in early clinical trials include bladder cancer, ovarian cancer, colorectal cancer,
breast cancer, HCC and pancreatic cancer, as shown in Table 1 [12]. This synergistic effect of
dual blockade results from the alteration of different signaling pathways within T cells, with
suppression of both Treg cells and inhibitory pathways within CTLs being thought of as the
primary mechanism of action [12]. The action of killer inhibitory receptors (KIRs), which
recognize MHC class I molecules and subsequently negatively regulate the cytotoxic activity of
NK cells, is another mechanism of avoiding immune surveillance in tumor cells through
retention of MHC class I expression [13]. Hence, KIR specific mAbs that are able to block this
negative regulation may provide a further combinatory target. T cell exhaustion may also be
overcome through tissue engineering approaches. For example, re-differentiation of
pluripotent stem cells into the T cell lineage, followed by transduction with engineered TCRs or
chimeric antigen receptors (CARs), has been shown to delay cancer progression in solid
tumors [14]. However, it is currently unclear if this method overcomes the issue of T cell
exhaustion. Interestingly, direct cell-cell contact between T cells and tumor cells has been
shown to induce T cell defects after short-term incubation, suggesting that severing this
contact may act to enhance T cell efficacy [15].
Trial Tumor type Therapy Clinical outcome
NCT03298451
 
Advanced
hepatocellular
carcinoma
Durvalumab plus
tremelimumab
Initial data from phase I/II trial suggests improved
objective response rate compared to durvalumab
alone.
NCT03434379
 
Advanced
hepatocellular
carcinoma
Atezolizumab plus
bevacizumab
Initial data from phase Ib trial suggests improved
response rate compared to monotherapy with either
agent.
NCT03713593
 
Advanced
hepatocellular
carcinoma
Pembrolizumab plus
lenvatinib
Initial data from phase Ib trial suggests good anti-
tumor response in unresectable tumors.
NCT02425891
 
Triple-negative
breast cancer
Atezolizumab plus
paclitaxel
Improved overall survival and progression-free survival
compared to monotherapy, particularly in PD-1
positive subgroup.
NCT03036488
 
Triple-negative
breast cancer
Pembrolizumab plus
chemotherapy regimen
Improved pathological complete response and event-
free survival compared to chemotherapy alone.
NCT01844505
 
Advanced
melanoma Nivolumab plus ipilimumab
Improved overall survival compared to ipilimumab
alone.
NCT02231749
 
Advanced renal
cell carcinoma Nivolumab plus ipilimumab
Improved overall survival and objective response rate
versus sunitinib.
NCT02853331
 
Advanced renal
cell carcinoma Pembrolizumab plus axitinib
Improved overall survival, progression free survival
and objective response rate versus sunitinib.
NCT02684006
 
Advanced renal
cell carcinoma Avelumab plus axitinib
Improved progression free survival compared to
sunitinib, though no improvement in overall survival.
NCT02420821
 
Advanced renal
cell carcinoma
Atezolizumab plus
bevacizumab
Improved progression free survival compared to
sunitinib.
NCT02985957
 
Metastatic
prostate cancer Nivolumab plus ipilimumab
Initial data from phase II trial suggests improved
objective response rate. 
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NCT02039674
 
Advanced non-
small cell lung
cancer
Pembrolizumab plus
carboplatin plus paclitaxel
Improved overall survival and progression free survival
compared to carboplatin and paclitaxel alone.
NCT01454102
 
Advanced non-
small cell lung
cancer
Nivolumab plus ipilimumab Improved progression free survival compared tochemotherapy treatment. 
NCT02542293
 
Advanced non-
small cell lung
cancer
Durvalumab plus
tremelimumab
No improvement in overall survival compared to
chemotherapy.
NCT02366143
 
Advanced non-
small cell lung
cancer
Atezolizumab plus
bevacizumab plus
carboplatin plus paclitaxel
Improved overall survival and progression-free survival
compared to bevacizumab plus carboplatin plus
paclitaxel.
NCT03214250
 
Metastatic
pancreatic
cancer
Nivolumab plus
gemcitabine plus paclitaxel
plus APX005M
Initial data from phase Ib trial suggests promising anti-
tumor response.
NCT03036098
 
Metastatic
bladder cancer Nivolumab plus ipilimumab
Improved overall survival and progression free survival
compared to chemotherapy.
NCT02807636
 
Advanced or
metastatic
bladder cancer
Atezolizumab plus
platinum-based
chemotherapy
Improved progression free survival compared to
atezolizumab alone.
NCT02498600
 
Recurrent
ovarian cancer Nivolumab plus ipilimumab
Initial data from phase II trial demonstrates improved
anti-tumor response compared to nivolumab alone.
NCT02580058
 
Recurrent
ovarian cancer
Avelumab plus doxorubicin
or platinum-based
chemotherapy
No improvement in overall survival or progression free
survival compared to chemotherapy.
NCT02788279
 
Metastatic
colorectal cancer
Atezolizumab plus
cobimetinib
No improvement in overall survival compared to
regorafenib.
NCT02060188
 
Metastatic
colorectal cancer Nivolumab plus ipilimumab
Initial data from phase II trial demonstrates promising
objective response rate.
TABLE 1: A summary of significant combination immunotherapy regimens currently
being explored in clinical trials
Another reason for the limited efficacy of immune checkpoint inhibitors in certain cancers may
relate to a poor Immunoscore, which is a scoring system that classifies cancers according to the
level of immune cell infiltration. The Immunoscore ranges from I0 or ‘cold’ for poorly infiltrated
tumors to I4 or ‘hot’ for well-infiltrated tumors. Hot tumors have been associated with
improved response rates to checkpoint blockade [16]. Hence, combinatory treatments that are
able to prime the immune system prior to checkpoint inhibitor therapy are another possible
approach to expand the role of immunotherapy. For example, agonistic targeting of
costimulatory receptors found on T cells, such as CD137 and OX40, enhances the anti-tumor
immune response by promoting T cell proliferation and survival [17-18]. Alternatively, T cells
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can be primed and expanded through the use of neoantigen-based vaccines or by targeting
cytokines, for example, dual IL-10 and PD-1 blockade is able to enhance the function of tumor-
specific CTLs [19]. Conventional treatments such as chemotherapy or radiotherapy may also
have a role in improving the response to immunotherapies, for example, as neoadjuvant
therapies. They are also able to upregulate the production of chemokines and cytokines,
increase the expression of MHC molecules, and facilitate tumor death, enabling the release of
tumor-associated antigens [12]. This, in turn, leads to enhanced antigen presentation, and T
cell recruitment and activation, which results in the upregulation of inhibitory immune
checkpoints. Other agents also have the potential to upregulate immune checkpoints and
enhance anti-tumor immunity. Such agents include 1) vascular endothelial growth factor
(VEGF) inhibitors, which are able to increase lymphocyte infiltration into tumors and reduce
expression of Treg cells, 2) adenosine (P1) receptor inhibitors, which increase APC activation
and reduce Treg cell expression, and 3) mitogen-activated protein kinase (MAPK) inhibitors,
which promote tumor cell death and the presentation of tumor-associated antigens by
enhancing MHC class I expression [12,20]. 
Another strategy to expand the use of immune checkpoint inhibitors is to target mechanisms of
resistance. For example, indoleamine 2,3-dioxygenase 1 (IDO1) has been implicated in
resistance to both anti-CTLA-4 and anti-PD-1 mAbs, though as of yet phase III trials have not
demonstrated any clinical improvements [21]. Mutations in immune effector signaling
pathways are also capable of suppressing the activity of tumor-specific T cells and provide
mechanisms of resistance to treatment. For example, mutations in Janus kinase 1 (JAK1) and
Janus kinase 2 (JAK2) are associated with loss of interferon-gamma (IFNγ) responsiveness and
antigen presentation. This has been shown to result in resistance to PD-1 blockade, which can
be overcome by inhibition of JAK1/2 signaling [22]. Downregulation of antigen presentation
may also be attributed to epigenetic changes, which may be overcome through the use of DNA
methylation inhibitors and histone deacetylase inhibitors [23]. Given the role of the gut
microbiome in regulating the mucosal immune system, it has also been shown to influence the
response to immune checkpoint inhibitors [24]. Consequently, modulating the gut microbiome,
for example, through fecal transplantation or simply by encouraging high-fiber diets in
patients, may further increase the efficacy of immune checkpoint inhibitors [25]. Interestingly,
however, recent evidence suggests that taking dietary supplements such as probiotics may
hinder the response to checkpoint inhibitors by lowering the diversity of the gut microbiome,
warranting further research in the area [25]. A summary of the various combinatory
immunotherapies discussed and their corresponding synergistic effects on the immune system
is provided in Figure 2. 
FIGURE 2: Combinatory immunotherapy approaches and their
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synergistic mechanisms of action
CAR, chimeric antigen receptor; CTLA-4, cytotoxic lymphocyte-associated protein 4;
IDO1, indoleamine 2,3-dioxygenase 1; JAK, Janus kinase; LAG3, lymphocyte activation gene 3
protein; MAPK, mitogen-activated protein kinase; PD-1, programmed cell death protein 1; TIM3, T
cell immunoglobulin and mucin domain-containing 3; Treg cells, regulatory T cells; VEGF, vascular
endothelial growth factor. 
Adoptive cell transfer and vaccines
Adoptive cell transfer (ACT) is another approach used in immunotherapy, where the patient’s
own T lymphocytes with anti-tumor activity are identified, expanded in vitro and re-infused
into the patient, often along with growth factors. CAR-T cell therapy is a particularly attractive
strategy, where the patient’s T cells are genetically engineered to express modified CARs that
target surface antigens whose epitope is unique to cancer cells. This approach is also attractive
in that CARs are HLA-independent, eliminating the need for haplotype matching. However,
while CAR-T therapy has had success in the treatment of hematological tumors, their
application in solid tumors has been largely limited [26]. This can firstly be attributed to the
lack of specific targetable antigens. For example, while CD19 has proven to be the most
successful target antigen for CAR-T cell therapy due to its ubiquitous expression in almost all B
cell malignancies, it is also expressed by non-malignant B cells [27]. However, fortunately, the
B cell aplasia and hypogammaglobulinemia associated with this lack of specificity can be easily
managed. Further barriers to CAR-T cell therapy include problems in T cell homing,
infiltration, and subsequent survival in the tumor microenvironment. Infiltration may be
improved through the engineering of CAR-T cells capable of degrading cellular components,
such as αvβ6 integrin, VEGF receptor 2 and heparan sulphate proteoglycans (through
heparanase release) [28-30]. 
To counteract the hostile and immunosuppressive nature of the tumor microenvironment, and
hence improve T cell survival, several strategies can be employed. Such strategies include
engineering CAR-T cells that 1) are resistant to TGF-β suppression via dominant-negative
TGF-β receptor expression, 2) can counteract the action of reactive oxygen species (ROS)
through catalase expression, reducing H2O2, and 3) can convert IL-4’s suppressive effects to a
stimulatory one through engineering chimeric receptors that express the IL-4 receptor
ectodomain [31-33]. CAR-T cell therapy may also provide a selective pressure, facilitating the
emergence of antigen loss variants with time [26,34]. This can be overcome by enabling the
CAR-T cells to target more than one antigen. For instance, through engineering the
extracellular portion of the CD16-chimeric receptor to express an FcγR domain, it is able to
bind to any therapeutic antibody directed against any tumor-associated antigen, triggering
both a cellular immune response and antibody-dependent cellular
cytotoxicity [35]. Alternatively, the two-component SUPRA CAR system has recently been
developed, which is composed of a receptor expressed on T cells (zipCAR) and an antigen-
binding component (zipFv). In this system zipCAR expressing T cells are activated once a zipFv
component containing a matching leucine zipper is added. SUPRA CARs are universal in that
multiple zipFv components expressing the same leucine zipper but different antigen-binding
domains can be added, allowing the targeting of multiple antigens. Thus, throughout the
course of therapy, antigen specificity can be altered depending on the patient response to
improve treatment efficacy [36]. 
A further strategy is the dual recognition of tumor-associated antigens expressed by the same
cell by two CARs [37,38]. As well as enhancing T cell activation, this approach may also be able
to reduce on-target/off-tumor toxicity by improving specificity to the target tumor, protecting
normal tissues. Alternatively, toxicity can be reduced by combining CARs directed against
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target antigens with inhibitory CARs (iCARS). The idea is that target antigens for CAR-T cell
therapy are also expressed by healthy tissues, albeit at lower levels compared to the tumor.
iCARS are able to produce inhibitory signals that can override this low level of T cell activation
against target antigens expressed by healthy cells, whilst enabling CAR-induced T cell
activation against tumor cells [37]. For example, the inhibitory receptors CTLA-4 and PD-1 can
be used in iCARs to negatively regulate the activation of T lymphocytes against normal tissue,
thus reducing off-target toxicity [39]. Toxicity associated with CAR-T cells may also relate to
the use of retroviral (RV) and lentiviral (LV) vectors, which may trigger immune and
inflammatory responses [40]. Instead, alternative systems, such as the transposons piggyBac
(PB) and Sleeping Beauty (SB) can be utilized, which also simplify and reduce the costs
associated with transduction [26]. Furthermore, as they do not utilize reverse transcription, the
likelihood of aberrant gene rearrangements is minimized. 
Most targeted antigens in immunotherapy are not tumor-selective and rather are just
overexpressed in tumors [26]. However, neoantigens are not encoded by the normal genome
and instead arise in tumors as a result of driver mutations and as by-products of increasing
genetic instability (passenger mutations), often rendering the pattern of expression as highly
unique to the individual [41]. Whilst this generally means neoantigens are not practical for
CAR-T therapy, distinct neoepitopes have been identified. For example, MUC-1 targeting CAR-
T cells have been shown to significantly delay tumor progression [42]. Furthermore,
neoantigen-directed T cells from a patient or donor can also be identified and expanded in
vitro for treatment, or alternatively T-cells can be genetically engineered to express
neoantigen-specific TCRs [43-44]. Enhancement of antigen presentation through stimulation
of the innate immune response and dendritic cell function, for instance by using type I IFN and
toll-like receptor (TLR) ligands, may also promote the formation and presentation of
neoantigens [45]. In turn, this may mount a more significant response by neoantigen-directed T
cells. These methods combined overcome the problem of a lack of suitable neoantigens and
alterations in antigen processing and/or presentation, which has been associated with impaired
anti-tumor activity [46].
Vaccine based approaches targeting neoepitopes can also be utilized, typically employing
synthetic peptides, DNA or RNA to encode the neoantigen. Whilst some neoantigens are shared
between various tumors and patients, the repertoire is rather small [47]. Consequently, this
largely limits the use of neoantigen-based vaccines for the treatment of cancer. However, with
the advent of next generation sequencing technologies, mutations specific to an individual
patient’s tumor can be identified, leading to the development of tailored neoantigen-based
vaccines. Such vaccines exert their effect through numerous mechanisms, including priming
the immune system and enhancing the response by CTLs [20,48]. Furthermore, poly-neoantigen
vaccines can be utilized to facilitate an augmented response. They may also be used to help
overcome the issue of tumor heterogeneity and minimize the risk of clonal expansion of
antigen loss variants of tumor cells, which can confer treatment resistance [47]. Through this
effect, neoantigen-based vaccines are able to act as a crucial adjunct for both ACT therapy and
treatment with immune checkpoint inhibitors [12,20].
Challenges and future directions
To facilitate the widespread adoption of immunotherapy for the treatment of cancer, a few
barriers must be overcome first. Most importantly, toxicity resulting from enhanced activation
of the immune system is an obstacle that prevents the regular use of immunotherapy,
particularly for combinatory regimens. Such immune-related adverse events (irAEs) include
acute episodes of autoimmune-like disease, as seen with immune checkpoint inhibitors,
making efficacy and safety studies essential when considering such therapies. Furthermore,
given the inherent complexity of tumors, preclinical models that accurately reflect the natural
course of tumor development and the associated immunosuppressive microenvironment must
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be utilized, such as genetically engineered mouse models. Consideration also needs to be given
to the route of delivery and other pharmacokinetic properties of immunotherapies in order to
maximize bioavailability to the target tumor site, for example through the use of nanoparticle
drug delivery systems. In addition, immunotherapy is often limited by the use of conventional
chemotherapy as first-line treatment. As a result, by the time, immunotherapy is utilized the
patient’s immune system may already be compromised due to advanced disease and/or previous
therapy. It is therefore essential that appropriate treatment regimens that optimize the dose,
schedule and duration of therapy are designed. 
Given the abundance of potential target molecules and the wide array of combinatory
therapies, it is imperative that biomarkers are developed to help predict tumor responses. This
will enable immunotherapy to be tailored to the individual patient, improving efficacy, and
reducing toxicity. For instance, in addition to CAR-T cell therapy, neoantigens may be utilized
as predictive biomarkers to identify tumors more amenable to checkpoint inhibitor therapy, due
to the correlation between the number of mutations/neoantigens and the therapeutic response
[49]. Similarly, tumor mutational burden and the presence of certain immune inhibitory
molecules such as PD-L1, CTLA-4, and IDO1 can be used to predict response to checkpoint
inhibitor blockade in a range of cancers, including NSCLC, renal cell carcinoma, bladder cancer,
and melanoma [50]. To facilitate a shift to an era of more personalized cancer therapy, cost-
effective and practical methods for identifying relevant biomarkers and/neoepitopes, and
categorizing cancers according to the underlying immunosuppressive mechanism, must be
developed. 
Conclusions
While immunotherapy is still very much in its infancy, it has already shown huge promise and
is well-aligned in becoming the mainstay treatment for cancer. In particular, the use of
combination therapies and strategies to boost the immune response appear to be particularly
attractive approaches, although careful consideration must be given to minimize the likelihood
of irAEs. Tailoring immunotherapy to the individual patient through the use of neoantigens
and predictive biomarkers should also be further explored in order to improve treatment
efficacy, whilst minimizing toxicity. Given the heterogeneous nature of tumors, it is crucial that
these different strategies are explored simultaneously and synergistically to ensure
immunotherapy lives up to its potential in improving the treatment for the majority of cancers. 
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